Ok if you read at the Quack often enough you know what an algorithm is but now we have a company that says an algorithm can address the type of treatment one should have so don’t get your bowels in an uproar with this one:) Of course this is a topic that nobody really likes to talk about, self included.
I do have to say this is quite the press release and again not mocking this at all as there are patients who may need the therapy but now an algorithm is going to determine the treatment it appears. In case your doctor does not know what to do they can rely on the algorithm to help them. I said a while back that some time in the future someone will design an algorithm for just about anything and it appears that time has come with an anal “decision tree” for treatment. This looks as if it is an educational press release to spread the word about Secca treatment to restore control to the sphincter area of the body with radio frequency energy . Actually I made a post in jest about a year ago about the use and abuse of data and perhaps this could fit into this category? Will we need a twelve step program soon for this phenomena?
Data Addiction and Abuse –The Up and Coming Next 12 Step Program Is On the Horizon–Side Effects Include Lack Of Data Quality, Integrity And Spasmodic Algorithms
Again if the doctor can’t figure it out, you now have an “anal algorithm” to help out now so what part of healthcare doesn’t have an algorithm today? So I want to ask at this point is this marketing or education, you tell me. BD
New Algorithmic Approach to Address Treatment of Fecal Incontinence
GREENWICH, Conn., Nov. 21, 2011 /PRNewswire/ -- In a new paper published today in Touch Gastroenterology, the researcher addresses the immediate need for a reasoned, stepwise algorithm for treating bowel control disorder (BCD), also known as fecal incontinence (FI). The review evaluates all aspects of the disease state, including some of the newer therapeutic alternatives and outlines the latest treatment algorithm. The review also cites several attempts to determine the true prevalence of this debilitating condition that is estimated to affect tens of millions of people worldwide. BCD has been identified as a common consequence of childbirth and the aging process and the second leading cause of institutionalization in the US.
"Determining what to do and when remains a critical unmet need for clinicians in addressing BCD," said Dr. Mark D. Noar, Director of the Bowel Control Disorder Center at Endoscopic Microsurgery Associates, Towson, MD. "This latest Fecal Incontinence Treatment Algorithm provides the roadmap on critical decision points to be made following unsuccessfully applied conservative methods or pharmacologic therapies."
"This algorithm is a significant advancement that includes all of the newer treatments and clearly outlines all available options for doctors and their patients," said Will Rutan, Mederi Therapeutics' CEO, maker of the Secca Therapy System for BCD. "This decision tree is a valuable tool that also supports the rationale for an alternate course of action, and specifically when Secca may be appropriate as an effective, less complicated and less invasive alternative for BCD."
Additional information is available at Touchgastroenterology.com; November, 2011, at the following link: http://www.touchgastroenterology.com/articles/chronic-faecal-incontinence-review-disease-state-therapeutic-alternatives-and-algorithmic-a and at www.mederitherapeutics.com.
Secca therapy is a minimally invasive and effective treatment that bridges the gap between conservative therapies and invasive surgery or implants for bowel control disorder (BCD). Secca involves delivery of radiofrequency energy to the internal anal sphincter, which results in a change in tissue compliance and corresponding improvement in incontinence symptoms. Numerous clinical studies have shown Secca to be a safe and effective therapeutic option. Secca does not preclude next steps with foreign implants or more invasive procedures when indicated.
Mederi Therapeutics manufactures and markets innovative medical devices that deliver radiofrequency energy to treat disease states affecting the human digestive system. All Mederi therapies are outpatient, minimally invasive, and promote rapid recovery. Mederi Therapeutics Inc. is located in Greenwich, Connecticut.